AKT1 mutation

P2, N=124, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

These features often create diagnostic challenges during preoperative biopsy, intraoperative frozen section analysis, and postoperative histopathological evaluation. Herein, we report a rare case of recurrent, multifocal PSP exhibiting sarcomatoid features and harboring a p.E17K mutation in the AKT1 gene.

P2, N=33, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

Lung cancer patients carrying co-occurrences of somatic mutation-CNVs in TP53 and KRAS showed poorer survival than those carrying the same gene mutations. These findings reveal epistasis of cancer mutations and CNVs at an allelic resolution, suggesting specific genomic events to enhance patient stratification and therapeutic targeting.

P2, N=45, Recruiting, National Human Genome Research Institute (NHGRI) | Trial completion date: Mar 2028 --> Jul 2028 | Trial primary completion date: Mar 2026 --> Jul 2026

Non-sinonasal ITACs are rare, aggressive malignancies requiring accurate diagnosis and further molecular investigation to improve management and outcomes.

Functional enrichment analysis highlights the therapeutic relevance of these hubs, while 5.8% of identified proteins are oncogenes, reinforcing their candidacy for therapies. This study provides a systematic, network-based framework for identifying and prioritizing hub proteins in the PI3K/Akt pathway, with potential implications for rational multi-target drug design in precision oncology.

However, the classification of the neoplasm remains a controversial issue, with the WHO noting that it is still not established whether SG IPMN should be classified separately or within the mucinous adenocarcinoma spectrum as a potential precursor [2]. We describe an unusual case of a minor salivary gland papillary mucinous neoplasm presenting in a novel location (subglottic larynx) with a novel mutational driver for this entity (GNAS R844H mutation), and briefly review the literature surrounding SG IPMN, its classification and related tumours.

In ESR1-mutant MBC, elacestrant treatment durations support the routine use of elacestrant monotherapy in appropriately selected patients. For patients with concurrent ESR1 and PI3K-pathway mutations, single-agent activity was comparable to outcomes observed in phase III studies.

Molecular analysis of the metastasis and original jaw lesion revealed a mutation of AKT1 (c.49G > A p.(Glu17Lys) COSMIC ID: COSM33765) but no mutations in the BRAF gene were identified. This case illustrates the critical necessity of a thorough clinical history of previous neoplasia, even many years following treatment, as well as the role of molecular profiling for identifying novel targeted treatment options.

P2, N=33, Recruiting, National Cancer Institute (NCI) | Active, not recruiting --> Recruiting